Ingredient or product comparison
GHK-Cu Cosmetic Metabolism Research: Study Comparison
J Drugs Dermatol 2015 3 µM 70% increase in collagen synthesis, 300% increase in COL1A1 gene expression TGF-β1 upregulation, SMAD signaling activation Demonstrates therapeutic threshold for fibroblast stimulation Biomaterials 2012 1–5 µM 230% increase in TGF-β1
This source-based comparison does not add ratings or recommend a winner.
- J Drugs Dermatol 2015
- 3 µM
- 70% increase in collagen synthesis, 300% increase in COL1A1 gene expression
- TGF-β1 upregulation, SMAD signaling activation
- Demonstrates therapeutic threshold for fibroblast stimulation
- Biomaterials 2012
- 1–5 µM
- 230% increase in TGF-β1 expression at 3 µM within 48 hours
- Direct cytokine modulation
- Establishes dose-response curve and optimal concentration window
- Clin Cosmet Investig Dermatol 2017
- 0.1–10 µM
- Maximum activity at 3 µM; cytotoxicity above 10 µM
- Oxidative stress, apoptosis markers
- Defines upper safety limit and therapeutic window
- Eur J Pharm Biopharm 2014
- Liposomal vs free peptide
- 4.2× higher dermal penetration with liposomal delivery
- Phospholipid vesicle fusion with cell membranes
- Addresses bioavailability challenge in topical formulations
- J Invest Dermatol 2018
- 2 µM + microneedling
- Increased dermal collagen density by 18% at 12 weeks (ultrasound-confirmed)
- Wound-healing amplification, direct dermal delivery
- Only method replicating in vitro results in vivo